Debt-to-equity of Lantern Pharma Inc. from 31 Mar 2021 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Lantern Pharma Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2021 to 30 Sep 2025.
  • Lantern Pharma Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 29%, a 162% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Lantern Pharma Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 29% +18% +162% 30 Sep 2025
Q2 2025 22% +13% +150% 30 Jun 2025
Q1 2025 18% +11% +149% 31 Mar 2025
Q4 2024 15% +8.6% +144% 31 Dec 2024
Q3 2024 11% +5.7% +102% 30 Sep 2024
Q2 2024 9% +3.4% +61% 30 Jun 2024
Q1 2024 7.2% +0.98% +16% 31 Mar 2024
Q4 2023 6% +0.05% +0.84% 31 Dec 2023
Q3 2023 5.6% +0.15% +2.8% 30 Sep 2023
Q2 2023 5.6% +0.95% +21% 30 Jun 2023
Q1 2023 6.2% +2.7% +78% 31 Mar 2023
Q4 2022 5.9% +3.4% +133% 31 Dec 2022
Q3 2022 5.4% +3% +127% 30 Sep 2022
Q2 2022 4.6% +2.1% +81% 30 Jun 2022
Q1 2022 3.5% +0.23% +7.1% 31 Mar 2022
Q4 2021 2.5% 31 Dec 2021
Q3 2021 2.4% 30 Sep 2021
Q2 2021 2.6% 30 Jun 2021
Q1 2021 3.2% 31 Mar 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.